Health care professionals review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) multiple myeloma revelations, spotlighting transformative trials, groundbreaking translational research, and clinical perspectives that illuminate the evolving treatment landscape.
Experts review groundbreaking insights from review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) and discuss the paradigm shift in myeloma frontline treatments, exploring quads, bispecifics, and the dynamic evolution of therapeutic approaches.
Experts discuss the evolving landscape of multiple myeloma treatment, exploring real-world evidence's role in shaping the future and its impact on clinical decisions, rare subgroups, and treatment sequencing.
A panel of experts discuss leveraging real-world data in multiple myeloma treatment decisions and explore the significance, limitations, and evolving role of real-world data, shedding light on patient experiences, access to care, and treatment outcomes beyond clinical trials.
Experts discuss findings from real-world studies comparing DRd with VRD, emphasizing the importance of individualized dosing and supportive care, and navigate challenges in incorporating real-world data.